EA016507B1 - Пиперидиновые агонисты gpcr - Google Patents

Пиперидиновые агонисты gpcr Download PDF

Info

Publication number
EA016507B1
EA016507B1 EA200900878A EA200900878A EA016507B1 EA 016507 B1 EA016507 B1 EA 016507B1 EA 200900878 A EA200900878 A EA 200900878A EA 200900878 A EA200900878 A EA 200900878A EA 016507 B1 EA016507 B1 EA 016507B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
alkyl
formula
Prior art date
Application number
EA200900878A
Other languages
English (en)
Russian (ru)
Other versions
EA200900878A1 (ru
Inventor
Мэттью Колин Тор Файф
Ревати Перпетуа Дживаратнам
Джон Кейли
Саймон Эндрю Суэйн
Original Assignee
Прозидион Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0700126A external-priority patent/GB0700126D0/en
Priority claimed from GB0708748A external-priority patent/GB0708748D0/en
Priority claimed from GB0719765A external-priority patent/GB0719765D0/en
Application filed by Прозидион Лимитед filed Critical Прозидион Лимитед
Publication of EA200900878A1 publication Critical patent/EA200900878A1/ru
Publication of EA016507B1 publication Critical patent/EA016507B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA200900878A 2007-01-04 2008-01-04 Пиперидиновые агонисты gpcr EA016507B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0700126A GB0700126D0 (en) 2007-01-04 2007-01-04 GPCR agonists
GB0708748A GB0708748D0 (en) 2007-05-08 2007-05-08 GPCR agonists
GB0719765A GB0719765D0 (en) 2007-10-10 2007-10-10 GPCR agonists
PCT/GB2008/050014 WO2008081208A1 (en) 2007-01-04 2008-01-04 Piperidine gpcr agonists

Publications (2)

Publication Number Publication Date
EA200900878A1 EA200900878A1 (ru) 2010-02-26
EA016507B1 true EA016507B1 (ru) 2012-05-30

Family

ID=39186140

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900878A EA016507B1 (ru) 2007-01-04 2008-01-04 Пиперидиновые агонисты gpcr

Country Status (7)

Country Link
US (1) US20100048625A1 (Direct)
EP (1) EP2114936A1 (Direct)
JP (1) JP2010514832A (Direct)
BR (1) BRPI0806312A2 (Direct)
CA (1) CA2674360A1 (Direct)
EA (1) EA016507B1 (Direct)
WO (1) WO2008081208A1 (Direct)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008000017A1 (es) * 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
JP2010539152A (ja) 2007-09-10 2010-12-16 プロシディオン・リミテッド 代謝障害の治療のための化合物
GB0812649D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812641D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812648D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
CN102089301A (zh) * 2008-07-10 2011-06-08 普洛希典有限公司 哌啶gpcr激动剂
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
JP2012530758A (ja) 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
EP2445878A1 (en) 2009-06-24 2012-05-02 Boehringer Ingelheim International GmbH New compounds, pharmaceutical composition and methods relating thereto
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB2488360A (en) * 2011-02-25 2012-08-29 Prosidion Ltd Heterocyclic GPCR agonists
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
ES2610362T3 (es) * 2011-01-25 2017-04-27 Viviabiotech, S.L. Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1
KR101913619B1 (ko) 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067531A1 (en) * 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
WO2007003962A2 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
WO2007116229A1 (en) * 2006-04-06 2007-10-18 Prosidion Limited Heterocyclic gpcr agonists

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US6100042A (en) * 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
WO2003020217A2 (en) 2001-08-31 2003-03-13 University Of Connecticut Novel pyrazole analogs acting on cannabinoid receptors
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
FR2829027A1 (fr) 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
KR100903760B1 (ko) 2001-09-21 2009-06-19 솔베이 파마슈티칼스 비. 브이 Ｃｂ1-길항 작용을 가지는 신규한4,5-디하이드로-1ｈ-피라졸 유도체
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
BR0208253A (pt) 2001-09-21 2004-04-13 Solvay Pharm Bv Compostos, composições farmacêuticas, método de preparação de composições farmacêuticas, processo para preparação de compostos, e, uso de um composto
FR2831883B1 (fr) 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
SE0104330D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104332D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
FR2833842B1 (fr) 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
WO2003063781A2 (en) 2002-01-29 2003-08-07 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
WO2003075660A1 (en) 2002-03-06 2003-09-18 Merck & Co., Inc. Method of treatment or prevention of obesity
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
AR038966A1 (es) 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
EP1490043A4 (en) 2002-03-26 2007-05-30 Merck & Co Inc SPIROCYCLIC AMIDS AS CANNABINOID RECEPTOR MODULATORS
ES2192494B1 (es) 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
US7271266B2 (en) 2002-03-28 2007-09-18 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
US20050154202A1 (en) 2002-04-05 2005-07-14 Hagmann William K. Substituted aryl amides
FR2838439B1 (fr) 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
FR2838438A1 (fr) 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
AU2003223510B2 (en) 2002-04-12 2008-05-08 Merck Sharp & Dohme Corp. Bicyclic amides
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
CA2493313C (en) 2002-07-29 2010-03-09 F. Hoffmann-La Roche Ag Novel benzodioxoles
EP1558252B1 (en) 2002-08-02 2007-10-10 Merck & Co., Inc. Substituted furo [2,3-b]pyridine derivatives
WO2004034968A2 (en) 2002-08-20 2004-04-29 The Regents Of The University Of California Combination therapy for controlling appetites
HRP20050053A2 (en) 2002-09-19 2005-04-30 Solvay Pharmaceuticals B.V. 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
JP2006510597A (ja) 2002-09-27 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 置換ピリミジン類
BR0314872A (pt) 2002-10-18 2005-08-02 Pfizer Prod Inc Ligandos do receptor canabinóide e usos dos mesmos
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
CA2510785C (en) 2002-12-19 2013-04-09 Merck & Co., Inc. Substituted amides
GB0230087D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
BR0317931A (pt) 2003-01-02 2005-11-29 Hoffmann La Roche Compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação dos receptores de cb1 e utilização dos compostos
ATE450505T1 (de) 2003-01-02 2009-12-15 Hoffmann La Roche Cb 1 rezeptor inversagonisten
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
DE502004007000D1 (de) 2003-02-13 2008-06-12 Sanofi Aventis Deutschland Stickstoff substituierte hexahydro-pyrazino 1,2-a pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP1599480B1 (de) 2003-02-13 2010-06-30 Sanofi-Aventis Deutschland GmbH Substituierte hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP1606019A1 (en) 2003-03-07 2005-12-21 The University Court of The University of Aberdeen Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
EP1711491A1 (en) * 2003-12-24 2006-10-18 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
EP1838706A1 (en) * 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor agonists
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
JP5114395B2 (ja) * 2005-06-30 2013-01-09 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
MX2007016545A (es) 2005-06-30 2008-02-21 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
WO2007003961A2 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
KR20090097184A (ko) * 2006-12-06 2009-09-15 스미스클라인 비참 코포레이션 비시클릭 화합물 및 항당뇨병제로서의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067531A1 (en) * 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
WO2007003962A2 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
WO2007116229A1 (en) * 2006-04-06 2007-10-18 Prosidion Limited Heterocyclic gpcr agonists

Also Published As

Publication number Publication date
EA200900878A1 (ru) 2010-02-26
JP2010514832A (ja) 2010-05-06
BRPI0806312A2 (pt) 2011-09-06
CA2674360A1 (en) 2008-07-10
WO2008081208A1 (en) 2008-07-10
EP2114936A1 (en) 2009-11-11
US20100048625A1 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
EA016507B1 (ru) Пиперидиновые агонисты gpcr
EA015129B1 (ru) Пиперидиновые агонисты gpcr
EA015130B1 (ru) Пиперидиновые агонисты gpcr
US8173807B2 (en) Pyridine, pyrimidine and pyrazine derivatives as GPCR agonists
EA015805B1 (ru) Пиперидиновые агонисты gpcr
EP2013201B1 (en) Heterocyclic gpcr agonists
US20100048631A1 (en) Piperidine GPCR Agonists
EP2318399B1 (en) Piperidinyl gpcr agonists
JP2009533410A (ja) Ｇタンパク質共役型受容体（ｇｐｒ１１９）アゴニストとしてのアゼチジン誘導体
ES2369944T3 (es) Agonistas de gpcr piperidínicos.
CN101627037A (zh) 哌啶gpcr激动剂
HK1157329B (en) Piperidinyl gpcr agonists
HK1135705B (en) Piperidine gpcr agonists

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU